



Ref: OPL/Share/2020/52  
May 20, 2020

**Managing Director**  
Chittagong Stock Exchange (CSE)  
CSE Building  
1080 SK Mujib Road, Agrabad,  
Chittagong.

**Subject : Price Sensitive Information.**

Dear Sir,

As per rule no. 33 of the CSE Listing Regulations, 2015, the Board of Directors of **Orion Pharma Limited** has adopted its **un-audited 3<sup>rd</sup> quarterly financial statements** in its Board Meeting held Today on May 20, 2020 at 11:00 am in the registered office at Orion House, 153-154, Tejgaon I/ A, Dhaka-1208. The following decisions were taken in the meeting :

		March 31, 2020		March 31, 2019	
Consolidated NAV per Share - Q3 (Including Revaluation Surplus)	:	BDT. 76.68		BDT. 74.29	
Consolidated NAV per Share - Q3 (Excluding Revaluation Surplus)	:	BDT. 68.57		BDT. 66.05	
		July 01, 2019 to March 31, 2020	July 01, 2018 to March 31, 2019	Jan 01, 2020 to March 31, 2020	Jan 01, 2019 to March 31, 2019
Consolidated Earnings Per Share (EPS)- Q3	:	BDT. 2.75	BDT. 3.01	BDT. 0.61	BDT. 0.95
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT. 2.73	BDT. 7.15	----	----

Please acknowledge the receipt.

Thanking you

Sincerely yours

**Md. Ferdous Jaman**  
Company Secretary